CARsgen Therapeutics announces share repurchase, substantial shareholder increases stake

CARsgen Therapeutics Holdings Limited has announced an updated share repurchase plan, authorizing the buyback of up to 25,461,295 shares within 50 Hong Kong trading days, commencing November 13, 2025. This updated plan, combined with shares already repurchased in 2025, represents 5% of the total issued shares. The company previously repurchased 3,310,500 shares under a prior plan.

The board believes the current share price undervalues the company's true worth and growth prospects, stating the repurchase demonstrates confidence from directors and senior management. Funds for the repurchase will originate from non-IPO sources including business development income, interest income, and other subsidies.

Additionally, YIJIE Biotech Holding Limited and its concert parties, a substantial shareholder, increased their stake by purchasing 100,000 shares between November 6 and November 10, 2025. This acquisition brings their total holding to 218,048,730 shares, approximately 37.92% of the total issued shares (excluding treasury shares), signaling strong confidence in CARsgen's long-term investment value.